Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-07-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cellscellsubjectscancerventricular
  Phrases that lowered it: lymphomasurfacerelapsedrelevantinfected
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 26 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 17.3% (lowers risk) · Drug's FDA history
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 94.9% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: 65 (lowers risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Sponsor's past trials: 12 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL NCT01874288 · started 2013 · scored riskier than 53% of active trials terminated
• Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma NCT04431635 · started 2020 · scored riskier than 58% of active trials terminated
• Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas NCT04933617 · started 2022 · scored riskier than 98% of active trials terminated
• A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) NCT02957019 · started 2013 · scored riskier than 96% of active trials terminated
• Rituximab + Immunotherapy in Follicular Lymphoma NCT03636503 · started 2018 · scored riskier than 72% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.